Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA.
Methods Mol Biol. 2021;2318:267-279. doi: 10.1007/978-1-0716-1476-1_14.
Cellular reprogramming is a process by which adult differentiated cells lose their identity and are converted into pluripotent stem cells, known as induced pluripotent stem (iPS) cells. This process can be achieved in vitro and in vivo and is relevant for many fields including regenerative medicine and cancer. Cellular reprogramming is commonly induced by the ectopic expression of a transcription factor cocktail composed by Oct4, Sox2, Klf4, and Myc (abbreviated as OSKM), and its efficiency and kinetics are strongly dependent on the presence of Myc. Here, we describe a versatile method to study reprogramming in vivo based on the use of adeno-associated viral (AAV) vectors, which allows the targeting of specific organs and cell types. This method can be used to test Myc mutations or genes that may replace Myc, or be combined with different Myc regulators. In vivo reprogramming can be scored by the presence of teratomas and the isolation of in vivo iPS, thereby providing a simple surrogate for the function of Myc in dedifferentiation and stemness. Our protocol can be divided into five steps: (1) intravenous inoculation of AAV vectors; (2) monitoring the animals until the appearance of teratomas; (3) analysis of teratomas; (4) histopathological analysis of mouse organs; and (5) isolation of in vivo-generated iPS cells from teratomas, blood, and bone marrow. The information obtained by this in vivo testing platform may provide relevant information on the role of Myc in tissue regeneration, stemness, and cancer.
细胞重编程是一个过程,通过这个过程,成年分化细胞失去其身份,并被转化为多能干细胞,称为诱导多能干细胞(iPS)细胞。这个过程可以在体外和体内实现,与许多领域相关,包括再生医学和癌症。细胞重编程通常通过异位表达由 Oct4、Sox2、Klf4 和 Myc(缩写为 OSKM)组成的转录因子鸡尾酒来诱导,其效率和动力学强烈依赖于 Myc 的存在。在这里,我们描述了一种基于腺相关病毒(AAV)载体的体内重编程研究的多功能方法,该方法允许针对特定器官和细胞类型进行靶向。该方法可用于测试 Myc 突变或可能替代 Myc 的基因,或与不同的 Myc 调节剂结合使用。体内重编程可以通过存在畸胎瘤和分离体内 iPS 来评分,从而为 Myc 在去分化和干细胞特性中的功能提供简单的替代。我们的方案可以分为五个步骤:(1)静脉注射 AAV 载体;(2)监测动物直至畸胎瘤出现;(3)分析畸胎瘤;(4)分析小鼠器官的组织病理学;(5)从畸胎瘤、血液和骨髓中分离体内产生的 iPS 细胞。通过这个体内测试平台获得的信息可能为 Myc 在组织再生、干细胞特性和癌症中的作用提供相关信息。